Figure 2
Transcriptional changes in human aortic endothelial cells after treatment with epinephrine. HAECs were treated with epinephrine (10 µM) or vehicle control for 7 h under normoxia (20% O2) using the perfusion system. RNA-sequencing was performed from RNA isolated 3 biological replicates. (a) Multidimensional scaling plot of differentially expressed genes in HAECs treated with epinephrine or vehicle control. LogFC dim 1, and dim 2: base 2 logarithm of fold change dimension 1 and 2. (b) Volcano plot of -Log10 (p values) vs. Log2 fold change for DEGs and top significantly upregulated genes upon epinephrine treatment. The -log10 (p values) represents the level of significance of each gene while log2 fold change represents the difference between the levels of expression for each gene. (c) Using qPCR, we measured mRNA expression of EFNA1, FABP4, PLA2G4C, CD34, Transcription factor jun-B (JUNB), Nuclear receptor subfamily 4 group A member 1 (NR4A1) and Interferon regulatory factor 1 (IRF1) in HAECs under control normoxia and IH (data are shown as mean ± SD, n = 6, biologic replicates). *p < 0.05. Parameters for DEG significance were set to absolute fold change ≥ 2 and FDR adjusted p value ≤ 0.05. Activated and suppressed gene (d) ontology biological processes (GO BP) and (e) activated and suppressed KEGG pathways were identified by gene set enrichment analysis of DEGs in HAECs treated with epinephrine compared to control treatment.
